FGFR2/3 mutations or fusions were evidently more frequent in upper tract UCs than in bladder carcinomas (10/21 (48%) vs. 30/147 (20%), p = 0.012), and in patients with localized disease compared to subjects with advanced or metastatic disease (29/99 (29%) vs. 16/9 9 (16%); p = 0.041). This evidence concerns the gene FGFR2 and urinary bladder carcinoma.